Surgery Partners (NASDAQ:SGRY) Given New $17.00 Price Target at Mizuho

Surgery Partners (NASDAQ:SGRY) had its target price cut by Mizuho from $19.00 to $17.00 in a research note published on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

Other research analysts have also recently issued reports about the company. Barclays dropped their target price on Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Weiss Ratings reissued a “sell (e+)” rating on shares of Surgery Partners in a report on Monday, December 29th. JPMorgan Chase & Co. cut their target price on shares of Surgery Partners from $27.00 to $20.00 and set a “neutral” rating for the company in a research report on Monday, November 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Surgery Partners in a report on Wednesday. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Surgery Partners in a research report on Wednesday. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $24.45.

Surgery Partners Trading Up 0.2%

Shares of SGRY stock opened at $14.11 on Thursday. The company has a current ratio of 1.87, a quick ratio of 1.72 and a debt-to-equity ratio of 1.15. Surgery Partners has a 12-month low of $12.25 and a 12-month high of $24.64. The stock has a market capitalization of $1.83 billion, a P/E ratio of -22.76 and a beta of 1.95. The firm’s 50 day moving average is $15.25 and its 200 day moving average is $18.21.

Surgery Partners (NASDAQ:SGRY) last announced its earnings results on Monday, March 2nd. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.19). The company had revenue of $885.00 million for the quarter, compared to analysts’ expectations of $866.54 million. Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. Surgery Partners’s quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.44 earnings per share. Research analysts expect that Surgery Partners will post 0.67 earnings per share for the current year.

Surgery Partners announced that its board has initiated a stock repurchase plan on Thursday, February 26th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 9.7% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Hedge Funds Weigh In On Surgery Partners

Several institutional investors have recently bought and sold shares of SGRY. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Surgery Partners by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 45,693 shares of the company’s stock worth $1,085,000 after purchasing an additional 2,015 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Surgery Partners by 1,253.7% in the first quarter. Millennium Management LLC now owns 202,274 shares of the company’s stock worth $4,804,000 after purchasing an additional 219,806 shares during the last quarter. Empowered Funds LLC lifted its position in shares of Surgery Partners by 11.0% in the first quarter. Empowered Funds LLC now owns 12,853 shares of the company’s stock worth $305,000 after buying an additional 1,278 shares in the last quarter. AlphaQuest LLC lifted its position in shares of Surgery Partners by 94.4% in the second quarter. AlphaQuest LLC now owns 2,057 shares of the company’s stock worth $46,000 after buying an additional 999 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in Surgery Partners by 7.5% during the second quarter. Envestnet Asset Management Inc. now owns 32,763 shares of the company’s stock valued at $728,000 after buying an additional 2,284 shares during the last quarter.

Key Surgery Partners News

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Company expansion and strategic deal — Surgery Partners completed the acquisition of Preferred Vascular Group (an ASC operator focused on dialysis-access procedures), expanding its ASC footprint and specialized services. ZIEGLER ADVISES PREFERRED VASCULAR GROUP ON ITS ACQUISITION BY SURGERY PARTNERS
• Positive Sentiment: Shareholder-friendly capital allocation — the board authorized a $200 million buyback (up to ~9.7% of shares), signaling management believes shares are undervalued and supporting EPS/ownership over time. Stock Buybacks
• Neutral Sentiment: Analysts still constructive but revising models — UBS, TD Cowen and Mizuho maintained buy/outperform ratings while cutting price targets (UBS to $21, TD Cowen to $20, Mizuho to $17), reflecting lowered near‑term expectations but continued confidence in recovery potential. Analyst Price Target Coverage TD Cowen PT Cut
• Neutral Sentiment: Earnings were mixed — Q4 showed revenue growth but margin pressures and an EPS miss, which explains both cautious analyst revisions and the short‑term stock weakness. Q4 2025 Earnings Call Highlights
• Negative Sentiment: Price targets and downside pressure — Barclays cut its target to $14 (roughly at the current level), adding downward pressure on sentiment. Barclays Lowers Price Target
• Negative Sentiment: Share price weakness and 52‑week low headlines — multiple outlets report SGRY hit a new 52‑week low after the disappointing earnings print, which can amplify selling and volatility. Sets New 52-Week Low MSN Coverage
• Negative Sentiment: Potential legal overhang — a law firm announced an investigation into possible claims against executives, which can elevate regulatory/legal risk and hurt sentiment until resolved. Johnson Fistel Investigation Notice

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.